AustraliaHealth

Biome Australia (ASX:BIO) has launched its multi-centre, international clinical trial for BMB18.

Noxopharm (ASX:NOX) shares surge on data showing its proprietary Sofra platform can amplify immune cells to actively fight cancer.

Osteopore (ASX:OSX) secured a major regulatory breakthrough, obtaining approval from the Hainan Medical Products Administration.

Ryman Healthcare (ASX:RYM) achieved its first positive free cash flow in over a decade, reaching NZ$188 million.

Cancer diagnostics company Pacific Edge (ASX:PEB) reported its audited financial results for the 2026 financial year.

HITIQ (ASX:HIQ) executed a non-dilutive grant agreement with the Victorian Government to heavily bolster its domestic operations.

Imugene (ASX:IMU) has released Phase 1b data for its innovative allogeneic CD19 CAR T-cell therapy, azer-cel.

PainChek (ASX:PCK) entered into binding agreements to raise $5.5 million through the issuance of unsecured convertible notes.

Bio-Gene Technology (ASX:BGT) announced an expansion of its vector control programmes into Asia.

Avecho Biotechnology (ASX:AVE) completed the treatment phase for its Phase 3 insomnia trial, keeping interim analysis results on track for late June.

OncoSil Medical (ASX:OSL) shares surge as the TGA approves its Class III pancreatic cancer device for commercialisation in Australia.

Fertility provider Monash IVF Group (ASX:MVF) announced the appointment of Dr Fleur Cattrall as its inaugural Chief Medical Officer.